Prognostic impact of presenting symptoms of patients with hepatocellular carcinoma

被引:0
|
作者
Lim, Samuel Jun Ming [1 ]
Hao, Ying [2 ]
Goh, George Boon Bee [1 ,3 ]
Chang, Jason Pik Eu [1 ,3 ]
Tan, Chee Kiat [1 ,3 ]
机构
[1] Singapore Gen Hosp, Dept Gastroenterol & Hepatol, Outram Rd, Singapore 169608, Singapore
[2] Natl Ctr Infect Dis, Natl Publ Hlth & Epidemiol Unit, Singapore, Singapore
[3] Duke NUS Med Sch, Singapore, Singapore
关键词
Carcinoma; hepatocellular; jaundice; oedema; prognosis; SURVIVAL; FEATURES;
D O I
10.4103/singaporemedj.SMJ-2021-283
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction:It is not known if the nature, number and duration of presenting symptoms at diagnosis of hepatocellular carcinoma impact on overall survival. This study examines whether the presenting symptoms of hepatocellular carcinoma have a significant impact on prognosis. Methods:The study cohort comprised 725 patients with symptomatic hepatocellular carcinoma seen in our department since October 1983. Another 545 patients were diagnosed on surveillance or from incidental findings. Presenting symptoms at diagnosis were documented. A survival census was performed on 31 October 2015 with the national registry of deaths. Presenting symptoms were examined for association with overall survival using multivariable Cox regression analysis. Survival analysis was done by Kaplan-Meier method with log-rank testing. Bivariate Pearson correlation was used to look for any association between duration of symptoms and overall survival. Results:Patients with symptomatic hepatocellular carcinoma had a significantly shorter survival than those diagnosed incidentally or on screening (94.0 vs. 786.0 days, P < 0.001). Survival was shorter in patients presenting with fluid retention (56.0 vs. 118.0 days, P < 0.001), jaundice (48.0 vs. 94.0 days, P = 0.017) and two or more symptoms (P = 0.010). Pain was associated with better survival (P < 0.001). On multivariable Cox regression analysis, only fluid retention (hazard ratio [HR] 1.56, 95% confidence interval [CI] 1.30-1.87) and jaundice (HR 1.36, 95% CI 1.07-1.74) were independently associated with shorter survival. There was no significant relationship between the duration of symptoms and overall survival. Conclusion:Patients with hepatocellular carcinoma who present with fluid retention or jaundice have significantly shorter overall survival. This is useful in assessing patients at the time of diagnosis.
引用
收藏
页码:444 / 448
页数:5
相关论文
共 50 条
  • [21] Novel Prognostic Biomarkers in Patients With Hepatocellular Carcinoma
    Schuette, Kerstin
    Treiber, Gerhard
    Neubueser, Frederik P.
    Link, Alexander
    Schulz, Christian
    Arend, Joerg
    Bretschneider, Tina
    Malfertheiner, Peter
    GASTROENTEROLOGY, 2015, 148 (04) : S937 - S938
  • [22] Prognostic Assessment of Patients with Untreated Hepatocellular Carcinoma
    Giannini, Edoardo G.
    Farinati, Fabio
    Ciccarese, Francesca
    Pecorelli, Anna
    Rapaccini, Gian Ludovico
    Di Marco, Mariella
    Caturelli, Eugenio
    Zoli, Marco
    Borzio, Franco
    Trevisani, Franco
    HEPATOLOGY, 2014, 60 : 872A - 872A
  • [23] Prognostic significance of periostin in patients with hepatocellular carcinoma
    Kaseb, Ahmed Omar
    Abugabal, Yehia I.
    Abdel-Wahab, Reham
    Lacin, Sahin
    Botrus, Gehan
    Pestana, Roberto Carmagnani
    Wolff, Robert A.
    Yao, James C.
    Hassan, Manal
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy
    Chia-Yang Hsu
    Yun-Hsuan Lee
    Yi-Hsiang Huang
    Cheng-Yuan Hsia
    Chien-Wei Su
    Han-Chieh Lin
    Rheun-Chuan Lee
    Yi-You Chiou
    Fa-Yauh Lee
    Teh-Ia Huo
    Shou-Dong Lee
    Hepatology International, 2013, 7 : 188 - 198
  • [25] Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor
    Guo, Yusheng
    Ren, Yanqiao
    Wu, Feihong
    Dong, Xiangjun
    Zheng, Chuansheng
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [26] Prognostic Impact of Intraoperative Blood Loss in Liver Transplant Patients with Advanced Hepatocellular Carcinoma
    Kornberg, Arno
    Witt, Ulrike
    Kornberg, Jennifer
    Ceyhan, Gueralp O.
    Mueller, Katharina
    Friess, Helmut
    Thrum, Katharina
    ANTICANCER RESEARCH, 2016, 36 (10) : 5355 - 5364
  • [27] Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor
    Guo, Yusheng
    Ren, Yanqiao
    Wu, Feihong
    Dong, Xiangjun
    Zheng, Chuansheng
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [28] Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy
    Hsu, Chia-Yang
    Lee, Yun-Hsuan
    Huang, Yi-Hsiang
    Hsia, Cheng-Yuan
    Su, Chien-Wei
    Lin, Han-Chieh
    Lee, Rheun-Chuan
    Chiou, Yi-You
    Lee, Fa-Yauh
    Huo, Teh-Ia
    Lee, Shou-Dong
    HEPATOLOGY INTERNATIONAL, 2013, 7 (01) : 188 - 198
  • [29] Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding
    Lang, BH
    Poon, RT
    Fan, ST
    Wong, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (11): : 2158 - 2165
  • [30] The impact of platelets on patients with hepatocellular carcinoma
    Scheiner, B.
    Popp, S.
    Hucke, F.
    Bota, S.
    Peck, M.
    Rohr-Udilova, N.
    Reiberger, T.
    Mueller, C.
    Trauner, M.
    Sieghart, W.
    Pinter, M.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S429 - S429